5 Key Takeaways
-
1
Diana Do, MD, presented data on geographic atrophy growth rates at the 2025 ASRS Annual Meeting.
-
2
The post hoc analysis of OAKS and DERBY trials showed fellow eyes grow at similar rates to sham-treated eyes.
-
3
This data supports using fellow eyes as a control group in clinical trials for bilateral geographic atrophy.
-
4
The analysis validates the growth rates of fellow eyes, reinforcing the reliability of projected sham treatments.
-
5
Early intervention with pegcetacoplan may enhance retinal preservation in patients with bilateral geographic atrophy.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
